Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01341457 | A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors | completed | Phase 1 | 17 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01007032 | A Study of IMC-A12 in Advanced Solid Tumors | completed | Phase 1 | 21 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02675478 |
| Phase 1 Study of Quizartinib |
| completed |
| Phase 1 |
| 17 |
| Daiichi Sankyo Co., Ltd.INDUSTRY |
| 1 |
| Feb 12, 2019 |
| clinicaltrials |
| NCT01456039 | A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 / Phase 2 | 51 | CelgeneINDUSTRY | 1 | Feb 11, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02690337 | Study of DS-1123a in Advanced Solid Tumours | completed | Phase 1 | 27 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | completed | Phase 1 | 7 | Puma Biotechnology, Inc.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02141347 | Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | completed | Phase 1 | 65 | AstraZenecaINDUSTRY | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01401530 | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | completed | Phase 1 | 13 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | completed | Phase 1 | 10 | Puma Biotechnology, Inc.INDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT02141659 | A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer | completed | Phase 1 | 43 | TakedaINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01764828 | BAY86-9766 Plus Gemcitabine Phase I Study in Asian | completed | Phase 1 | 23 | BayerINDUSTRY | 3 | Nov 1, 2018 | clinicaltrials |
| NCT02366546 | Investigator Initiated Phase 1 Study of TBI-1301 | unknown | Phase 1 | 9 | Mie UniversityOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 15, 2018 | clinicaltrials |
| NCT03213054 | A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer | unknown | Phase 1 | 12 | Oncolys BioPharma IncINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00742105 | Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT00397046 | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | completed | Phase 1 | 21 | Puma Biotechnology, Inc.INDUSTRY | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00371488 | GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00462956 | GW572016 In Patients With Advanced Or Metastatic Breast Cancer | completed | Phase 1 | 59 | GlaxoSmithKlineINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01241461 | A Study of LY2584702 in Solid Tumors | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01348347 | BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01662505 | Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT02201329 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 1 | 5 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01933516 | GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 6 | SandozINDUSTRY | 1 | Jul 26, 2018 | clinicaltrials |
| NCT02536586 | A Study of LY3023414 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | completed | Phase 1 | 6 | Puma Biotechnology, Inc.INDUSTRY | 1 | Jun 28, 2018 | clinicaltrials |
| NCT03082053 | A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours | completed | Phase 1 | 24 | ASLAN PharmaceuticalsOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT02678260 | Phase I Study of PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02485119 | Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | completed | Phase 1 | 12 | BayerINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02210663 | A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors | completed | Phase 1 | 16 | AbbVieINDUSTRY | 1 | May 7, 2018 | clinicaltrials |
| NCT02592785 | Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 9 | BayerINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01241292 | Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 15, 2018 | clinicaltrials |
| NCT01704963 | A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms | completed | Phase 1 | 15 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02151721 | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer(VICTORY-J) | unknown | Phase 1 | 12 | Kanazawa UniversityOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02363855 | Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects | completed | Phase 1 | 9 | BayerINDUSTRY | 1 | Jan 25, 2018 | clinicaltrials |
| NCT02359058 | A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer | completed | Phase 1 | 18 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 24, 2018 | clinicaltrials |
| NCT01813474 | Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 23 | AstraZenecaINDUSTRY | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT00921869 | A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Eisai Co., Ltd.INDUSTRY | 1 | Dec 26, 2017 | clinicaltrials |
| NCT01404390 | Japanese BAY80-6946 Monotherapy Phase I Study | completed | Phase 1 | 10 | BayerINDUSTRY | 1 | Dec 14, 2017 | clinicaltrials |
| NCT02272738 | A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer | completed | Phase 1 | 54 | Osaka Medical Center for Cancer and Cardiovascular DiseasesOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01617928 | A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | completed | Phase 1 | 12 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00742144 | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 6 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01297998 | A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy | completed | Phase 1 | 24 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00406757 | Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma | completed | Phase 1 | 13 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01324258 | Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | completed | Phase 1 | 19 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01582997 | A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT02013362 | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | completed | Phase 1 / Phase 2 | 25 | Mundipharma K.K.INDUSTRY | 1 | Nov 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials